Powered by Google

Sorry, something went wrong and the translator is not available.

Sorry, something went wrong with the translation request.

loading Translating

 
Bedinvetmab (Librela™)
Dawn Boothe, DVM, PhD, DACVIM, DACVCP
Published: April 26, 2024

(For veterinary information only)

WARNING
The size of the tablet/medication is NOT an indication of a proper dose. Never administer any drug without your veterinarian's input. Serious side effects or death can occur if you use drugs on your pet without your veterinarian's advice. 

It is our policy not to give dosing information over the Internet.

Brand Name: LibrelaTM in the US; Beransa in Australia

Available in 5, 10, 15, 20, or 30 mg/mL sterile injectable solution

Single-use vials without preservatives

Uses of this Medication

Bedinvetmab is indicated for the relief of osteoarthritis pain in dogs. 

  • It is given by your veterinarian as a once-a-month subcutaneous (under the skin) injection.
  • Dosage is determined by the dog’s weight.

How this Medication Works

The active substance in LibrelaTM is bedinvetmab, a monoclonal antibody (a type of protein made in the laboratory) designed to recognize and attach to a protein produced in your dog’s body called nerve growth factor (NGF). Once attached, bedinvetmab prevents NGF from attaching to its receptors (targets) on nerve cells and interrupts the transmission of pain signals. It also helps decrease inflammation.

Side Effects

  • Because it is an antibody, the body handles bedinvetmab much differently than other drugs. This reduces the risk of side effects and drug interactions.
  • Possible pain at the injection site, dermatitis (skin inflammation),  bacterial skin infection, urinary tract infections.

Interactions with Other Drugs

  • No interactions were seen in field studies where this veterinary medicinal product was administered along with veterinary products containing parasiticides, antimicrobials, topical antiseptics with or without corticosteroids, antihistamines, and vaccines.
  • If vaccines are to be administered at the same time as the injection of bedinvetmab, injections should be given at different sites to reduce any potential impact of immunogenicity (immune response) of a vaccine.

Contraindications

  • Not intended for use in dogs under 12 months of age.
  • Not intended for use in dogs intended for breeding.
  • Contraindicated in pregnant or lactating dogs.

Concerns and Cautions

It is not recommended that owners give the bedinvetmab injection to pets themselves. Women who are pregnant, trying to conceive, or breastfeeding should take particular care to avoid self-injection, as hypersensitivity reactions like anaphylaxis (allergic reaction) could potentially result.

Vials should be discarded after being punctured.

Because bedinvetmab is administered only at your veterinarian’s office, pet owners will not be concerned with the drug’s storage or disposal of used vials.

The content of this site is owned by Veterinary Information Network (VIN®), and its reproduction and distribution may only be done with VIN®'s express permission.

The information contained here is for general purposes only and is not a substitute for advice from your veterinarian. Any reliance you place on such information is strictly at your own risk.

Links to non-VIN websites do not imply a recommendation or endorsement by VIN® of the views or content contained within those sites.

Top
SAID=27